Y Zhao1, L Peng1, Y Luo1, S Li1, Z Zheng1, R Dong1, J Zhu1, J Liu2. 1. Department of Cardiology, the Third Affiliated Hospital, Sun Yat-sen University, Tian-he Road, 510630, Guangzhou, China. 2. Department of Cardiology, the Third Affiliated Hospital, Sun Yat-sen University, Tian-he Road, 510630, Guangzhou, China. liujlgz@yeah.net.
Abstract
AIM: This study aimed to evaluate the effect of trimetazidine (TMZ) in addition to standard treatment on exercise tolerance in patients with ischemic heart disease (IHD). METHODS: Studies were identified via a systematic search of PubMed, Embase, Cochrane Library, and the Chinese CNKI databases from January 1978 to January 2015. Data extraction, synthesis, and statistical analysis were performed by standard meta-analysis methods. Random or fixed effects models were used to estimate pooled mean differences in total exercise duration (TED), peak oxygen uptake (pVO2), metabolic equivalent system (METS), and 6-minute walking test (6-MWT). RESULTS: In all, 16 randomized controlled trials (RCTs) consisting of 2,004 participants were included. Pooled results showed that TMZ treatment significantly improved TED (WMD: 37.35, 95 % CI: 25.58-49.13, p < 0.00001), pVO2 (WMD: 2.41, 95 % CI: 1.76-3.06, p < 0.00001), METS (WMD: 1.33, 95 % CI: 0.38-2.28, p = 0.006), and 6-WMT (WMD: 62.46, 95 % CI: 35.86-89.05, p < 0.001) in all patients with IHD. Subgroup analysis showed that TMZ significantly increased TED in nondiabetic participants (WMD 34.77, 95 % CI: 22.28-47.25, p < 0.001), but not in diabetic participants (WMD: 40.36, 95 % CI: - 18.76-99.48, p = 0.18). And, subgroup analysis of TED by intervention duration suggested that there is no statistically difference between the 3-month and 6-month periods (WMD: 35.47, 95 %CI: 18.35-52.60, p < 0.0001 and WMD: 49.94, 95 %CI: 44.69-55.19, p < 0.00001). In addition, TMZ improved TED (WMD: 50.01, 95 % CI: 44.77-55.25 and WMD: 24.20, 95 % CI: 12.72-35.68) in IHD patients with or without heart failure (HF), respectively. CONCLUSION: Addition of TMZ to standard treatment significantly improved exercise tolerance in patients with IHD, and IHD patients with HF may experience even more benefits. However, there is insufficient evidence to show that TMZ has beneficial effects in participants with diabetes.
AIM: This study aimed to evaluate the effect of trimetazidine (TMZ) in addition to standard treatment on exercise tolerance in patients with ischemic heart disease (IHD). METHODS: Studies were identified via a systematic search of PubMed, Embase, Cochrane Library, and the Chinese CNKI databases from January 1978 to January 2015. Data extraction, synthesis, and statistical analysis were performed by standard meta-analysis methods. Random or fixed effects models were used to estimate pooled mean differences in total exercise duration (TED), peak oxygen uptake (pVO2), metabolic equivalent system (METS), and 6-minute walking test (6-MWT). RESULTS: In all, 16 randomized controlled trials (RCTs) consisting of 2,004 participants were included. Pooled results showed that TMZ treatment significantly improved TED (WMD: 37.35, 95 % CI: 25.58-49.13, p < 0.00001), pVO2 (WMD: 2.41, 95 % CI: 1.76-3.06, p < 0.00001), METS (WMD: 1.33, 95 % CI: 0.38-2.28, p = 0.006), and 6-WMT (WMD: 62.46, 95 % CI: 35.86-89.05, p < 0.001) in all patients with IHD. Subgroup analysis showed that TMZ significantly increased TED in nondiabetic participants (WMD 34.77, 95 % CI: 22.28-47.25, p < 0.001), but not in diabeticparticipants (WMD: 40.36, 95 % CI: - 18.76-99.48, p = 0.18). And, subgroup analysis of TED by intervention duration suggested that there is no statistically difference between the 3-month and 6-month periods (WMD: 35.47, 95 %CI: 18.35-52.60, p < 0.0001 and WMD: 49.94, 95 %CI: 44.69-55.19, p < 0.00001). In addition, TMZ improved TED (WMD: 50.01, 95 % CI: 44.77-55.25 and WMD: 24.20, 95 % CI: 12.72-35.68) in IHD patients with or without heart failure (HF), respectively. CONCLUSION: Addition of TMZ to standard treatment significantly improved exercise tolerance in patients with IHD, and IHD patients with HF may experience even more benefits. However, there is insufficient evidence to show that TMZ has beneficial effects in participants with diabetes.
Authors: H Szwed; Z Sadowski; W Elikowski; A Koronkiewicz; A Mamcarz; W Orszulak; E Skibińska; K Szymczak; J Swiatek; M Winter Journal: Eur Heart J Date: 2001-12 Impact factor: 29.983
Authors: E I Chazov; V K Lepakchin; E A Zharova; S B Fitilev; A M Levin; E G Rumiantzeva; T B Fitileva Journal: Am J Ther Date: 2005 Jan-Feb Impact factor: 2.688
Authors: Pericle Di Napoli; Paolo Di Giovanni; Marta Assunta Gaeta; Giuseppina D'Apolito; Antonio Barsotti Journal: Am Heart J Date: 2007-09 Impact factor: 4.749
Authors: G Fragasso; P M Piatti Md; L Monti; A Palloshi; E Setola; P Puccetti; G Calori; G D Lopaschuk; A Margonato Journal: Am Heart J Date: 2003-11 Impact factor: 4.749
Authors: Lucia Gatta; Laura Vitiello; Stefania Gorini; Sergio Chiandotto; Paola Costelli; Anna Maria Giammarioli; Walter Malorni; Giuseppe Rosano; Elisabetta Ferraro Journal: Oncotarget Date: 2017-12-08